Chapter 1 Introduction ....................................................... 1 Gordon M. Cragg, David G.I. Kingston, and David J. Newman Chapter 2 Camptothecin and Its Analogs ....................................... 5 Nicolas J. Rahier, Craig J. Thomas, and Sidney M. Hecht Chapter 3 The Discovery and Development of the Combretastatins .............. 23 Kevin G. Pinney, Christopher Jelinek, Klaus Edvardsen, David J. Chaplin, and George R. Pettit Chapter 4 Homoharringtonine and Related Compounds ........................... 47 Hideji Itokawa, Xihong Wang, and Kuo-Hsiung Lee Chapter 5 Podophyllotoxins and Analogs ...................................... 71 Kuo-Hsiung Lee and Zhiyan Xiao Chapter 6 Taxol and Its Analogs ............................................. 89 David G.I. Kingston Chapter 7 The Vinca Alkaloids .............................................. 123 Francoise Gueritte and Jacques Fahy Chapter 8 The Bryostatins .................................................. 137 David J. Newman Chapter 9 The Isolation, Characterization, and Development of a Novel Class of Potent Antimitotic Macrocyclic Depsipeptides: The Cryptophycins ................................................ 151 Rima S. Al-awar and Chuan Shih Chapter 10 Chemistry and Biology of the Discodermolides, Potent Mitotic Spindle Poisons ................................................. 171 Sarath P. Gunasekera and Amy E. Wright Chapter 11 The Dolastatins: Novel Antitumor Agents from Dolabella auricularia ..................................................... 191 Erik Flahive and Jayaram Srirangam Chapter 12 Ecteinascidin 743 (ET-743; YondelisTM), Aplidin, and Kahalalide F .................................................... 215 Ruben Henriquez, Glynn Faircloth, and Carmen Cuevas Chapter 13 Discovery of E7389, a Fully Synthetic Macrocyclic Ketone Analog of Halichondrin B ........................................ 241 Melvin J. Yu, Yoshito Kishi, and Bruce A. Littlefield Chapter 14 HTI-286, A Synthetic Analog of the Antimitotic Natural Product Hemiasterlin .................................................... 267 Raymond J. Andersen and Michel Roberge Chapter 15 The Actinomycins ................................................ 281 Anthony B. Mauger and Helmut Lackner Chapter 16 Anthracyclines .................................................. 299 Federico Maria Arcamone Chapter 17 Ansamitocins (Maytansinoids) .................................... 321 Tin-Wein Yu and Heinz G. Floss Chapter 18 Benzoquinone Ansamycins ......................................... 339 Kenneth M. Snader Chapter 19 Bleomycin Group Antitumor Agents ................................ 357 Sidney M. Hecht Chapter 20 Biochemical and Biological Evaluation of (+)-CC-1065 Analogs and Conjugates with Polyamides .................................. 383 Rohtash Kumar and J.William Lown Chapter 21 Epothilone, a Myxobacterial Metabolite with Promising Antitumor Activity .............................................. 413 Gerhard Hofle and Hans Reichenbach Chapter 22 Enediynes ....................................................... 451 Philip R. Hamann, Janis Upeslacis, and Donald B. Borders Chapter 23 The Mitomycins .................................................. 475 William A. Remers Chapter 24 Staurosporines and Structurally Related Indolocarbazoles as Antitumor Agents ................................................ 499 Michelle Prudhomme Chapter 25 Combinatorial Biosynthesis of Anticancer Natural Products ....... 519 Michael G. Thomas, Kathryn A. Bixby, and Ben Shen Chapter 26 Developments and Future Trends in Anticancer Natural Products Drug Discovery .................................................. 553 David J. Newman and Gordon M. Cragg Index ...................................................................... 573